

The Priority-driven Collaborative Cancer Research Scheme (PdCCRS)

What is the PdCCRS?

The Priority-driven Collaborative Cancer Research Scheme (PdCCRS) is an annual, national, priority-driven research grants scheme which brings together Cancer Australia and other funders of cancer research to coordinate and maximise investment in cancer research across Australia.

The PdCCRS funds:

- Three-year project grants, or
- One- or two-year project grants from young researchers.

PdCCRS three-year project grants are designed to support cancer research which will have a direct impact on clinical practice, policy and patient outcomes.

Purpose

The PdCCRS funds research which can help reduce the impact of cancer in the community and improve outcomes for all Australians affected by cancer.

The PdCCRS funds priority-driven cancer research projects which are:

- Outcomes and impact focused;
- Translatable into clinical practice, policy and/or further research,
- Collaborative; and
- Foster consumer participation in cancer research, from design to implementation.

PdCCRS Research priorities

Each funding partner identifies its own research priority areas.

Cancer Australia's research priorities are evidence-based, and were developed in consultation with advisory groups and approved by the Minister for Health.

How the scheme operates

Cancer Australia has joined with the National Health and Medical Research Council (NHMRC) to facilitate registration and assessment of PdCCRS applications.

Grants are assessed in a two-step process:

Step 1 – NHMRC assesses grant applications for scientific quality, significance / innovation and team quality and capability relevant to the application.

Step 2 – Grant Review Committees constituted by Cancer Australia and its Funding Partners review applications for outcomes and impact, translation, collaboration, and consumer involvement.

NHMRC endorses grant applications funded through this scheme in recognition of scientific merit.

Awarded grants 2007 - 2017

351 grants awarded - \$124 million

Cancer Australia has funded or co-funded 78% of these grants.